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OBJECTIVES The present study evaluates the impact of total cholesterol (TC) and its subfractions on
coronary flow reserve (CFR), an index of the integrated function of the coronary circulation,
in asymptomatic subjects.
BACKGROUND Endothelial dysfunction of the coronary microcirculation has been reported in asymptomatic
subjects with hypercholesterolemia.
METHODS Using oxygen-15-labeled water and positron emission tomography, myocardial blood flow
(MBF, in ml/min per g) was measured at rest and during intravenous adenosine (140 mg/kg
body weight per min) in 80 asymptomatic nonsmoking men: group 1 (n 5 61; age 45 6 7
years) had normal TC (#6.5 mmol/liter or #250 mg/dl) and group 2 (n 5 19; age 48 6 10
years) had elevated TC.
RESULTS Total cholesterol were 5.1 6 0.8 and 7.2 6 0.7 mmol/liter in groups 1 and 2 (p , 0.0005),
respectively; low density lipoprotein (LDL) cholesterol levels were 3.2 6 0.8 and 4.9 6 0.7
mmol/liter (p , 0.0005); high density lipoprotein (HDL) cholesterol levels were 1.1 6 0.3
and 1.0 6 0.4 mmol/liter (p 5 NS); and triglyceride levels were 1.8 6 1.3 and 3.0 6 1.8
mmol/liter (p , 0.005). Groups 1 and 2 did not differ with regard to MBF at rest (0.87 6
0.14 vs. 0.84 6 0.14), MBF during adenosine (3.63 6 1.02 vs. 3.30 6 0.86) or CFR (4.23 6
1.29 vs. 3.95 6 0.93). A significant but weak correlation was found between CFR and HDL
in group 1 (r 5 0.29, p , 0.05), but not in group 2. In contrast, a significant inverse
correlation between LDL and CFR was found in group 2 (r 5 20.61, p , 0.05), but not in
group 1.
CONCLUSIONS Low density lipoprotein cholesterol but not TC correlated inversely with CFR in hypercho-
lesterolemic subjects. Thus, LDL-induced coronary microvascular dysfunction could play an
important role in the pathogenesis of coronary artery disease and its complications. (J Am
Coll Cardiol 2000;36:103–9) © 2000 by the American College of Cardiology
In angiographically normal coronary arteries, hypercholes-
terolemia impairs endothelial-mediated coronary dilation
(1,2). This is, at least in part, reversible by L-arginine
infusion (3,4) and therapy with lipid-lowering drugs (5–8)
or calcium channel blockers (9). Similarly, by using positron
emission tomography (PET), a reduction in coronary flow
reserve (CFR) has been documented in hypercholester-
olemic asymptomatic subjects with normal coronary arteries
(10,11), as well as its reversibility with the use of
cholesterol-lowering strategies (12–14). However, from re-
sults obtained in vitro, endothelial dysfunction has been
specifically attributed to attenuation of nitric oxide release or
the initiation of superoxide anion production by oxidized
low density lipoprotein (LDL) cholesterol (15,16), or both,
rather than by an increase in total cholesterol (TC). In fact,
single LDL apheresis in humans has been shown to improve
endothelium-dependent vasodilation in hypercholester-
olemic patients (17). Thus, the aim of the present study was
to evaluate the correlation between TC, including each lipid
subfraction, and CFR as assessed with PET.
METHODS
Study group. Eighty asymptomatic male volunteers were
included in the present analysis. Sixty-one subjects who had
normal cholesterol (,6.5 mmol/liter or 250 mg/dl) served
as the control group (group 1; age 45 6 7 years). Nineteen
subjects with elevated cholesterol ($6.5 mmol/liter or
250 mg/dl; according to the inclusion criteria in West Of
Scotland COronary Prevention Study (WOSCOPS) [18])
comprised group 2 (age 48 6 10 years). None of the subjects
had a history of cardiovascular disease or coronary risk
factors (except for hypercholesterolemia). Entry criteria
included a normal heart rate, blood pressure, electrocardio-
gram (ECG) and two-dimensional echocardiogram, as well
as a low clinical probability for coronary artery disease (19).
In addition, all subjects were carefully instructed to
refrain from intake of caffeine-containing beverages within
24 h before the study. A screening test for caffeine was
performed on a blood sample taken immediately before the
PET scan from each subject. Caffeine was not detectable in
any of the blood samples.
Positron emission tomography. Scanning was performed
with an ECAT 931-08/12, 15-slice tomograph giving a
10.5-cm axial field of view (CTI/Siemens, Knoxville, Ten-
nessee), the characteristics of which have been reported
previously (20,21). Myocardial blood flow was measured
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using oxygen-15-labeled water (H2
15O), as reported else-
where (22,23). Briefly, H2
15O (700 to 900 MBq) was
injected as an intravenous bolus over 20 s at an infusion rate
of 10 ml/min, and the venous line was then flushed for
another 2 min with saline. The following acquisition frame
times were used: 14 3 5, 3 3 10, 3 3 20 and 4 3 30 s.
To define regions of interest, myocardial and blood pool
images were then generated directly from the dynamic
H2
15O study, as reported previously (24). Subsequently,
regions of interest were drawn within the left atrium and
ventricular myocardium on consecutive image planes. These
were projected onto the dynamic H2
15O images to generate
blood and tissue time-activity curves. These curves were
fitted to a single tissue-compartment tracer kinetic model to
give values of myocardial blood flow (ml/g per min), as
previously described (25). For the measurement of MBF,
the entire left ventricle was involved to obtain a value
representing the global left ventricle myocardial flow. The
reproducibility of this technique has been documented
recently (26).
The study protocol was approved by the Research Ethics
Committee of Hammersmith Hospital, and radiation expo-
sure was licensed by the U.K. Administration of Radioactive
Substances Advisory Committee (ARSAC). All patients
gave written, informed consent before the study.
Coronary flow reserve. Myocardial blood flow was mea-
sured at rest and during pharmacologically induced hyper-
emia using IV adenosine at a rate of 140 mg/kg body weight
per min (27). Arterial blood pressure was recorded with an
automatic cuff sphygmomanometer at 1-min intervals, and
the ECG was monitored continuously throughout the
procedure. A 12-lead ECG was recorded at baseline and
every minute during adenosine administration.
Coronary flow reserve was calculated as the ratio of
hyperemic to baseline MBF. To account for the variability
of coronary driving pressure, coronary resistance (mm
Hg/ml per min per g) was also calculated as the ratio of
mean arterial pressure to MBF.
Statistical analysis. Intergroup comparisons of hemody-
namic and PET data at rest and during adenosine were
carried out by two-way analysis of variance (ANOVA) for
continuous variables, followed by the Scheffe´ F test when
the ANOVA test was significant (p , 0.05). Univariate
analysis of the influence of cholesterol and its subfractions
on CFR was performed with the use of linear regression.
Data are reported as the mean value 6 SD.
RESULTS
All procedures were well tolerated, apart from the common
side effects caused by adenosine, such as flushing and chest
tightness.
Subject characteristics. Gender distribution (all men), age
and risk factors for coronary artery disease were comparable
between the two groups (except for hypercholesterolemia).
Because of the selection criteria, total serum and LDL
cholesterol levels, as well as triglyceride levels, were signif-
icantly lower in control subjects than in hypercholester-
olemic subjects (Table 1).
Hemodynamic data. Heart rate and mean arterial blood
pressure were similar in control subjects and hypercholes-
terolemic subjects both at rest and during adenosine. The
rate–pressure product did not differ between the two groups,
neither at rest nor during adenosine (Table 2).
Myocardial blood flow and CFR. Mean values of MBF
and CFR for both groups are summarized in Table 3. Rest
and hyperemic MBF values were similar in control subjects
and hypercholesterolemic subjects, resulting in a similar
CFR in both groups (4.23 6 1.29 vs. 3.95 6 0.93, relative
values; p 5 NS), with no correlation with TC or LDL
cholesterol (Fig. 1). There was a significant, although weak,
correlation between CFR and high density lipoprotein
(HDL) cholesterol in normocholesterolemic (r 5 0.29, p ,
Abbreviations and Acronyms
CFR 5 coronary flow reserve
ECG 5 electrocardiogram
H2
15O 5 oxygen-15-labeled water
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
MBF 5 myocardial blood flow
PET 5 positron emission tomography
TC 5 total cholesterol
Table 1. Subject Characteristics
Control Subjects
(n 5 61)
Hypercholesterolemic Subjects
(n 5 19) p Value
Age (yrs) 45 6 7 48 6 10 NS
Body mass index (kg/m2) 26 6 4 27 6 3 NS
Total cholesterol (mmol/liter) 5.1 6 0.8 7.2 6 0.7 ,0.0005
HDL cholesterol (mmol/liter) 1.1 6 0.3 1.0 6 0.4 NS
LDL cholesterol (mmol/liter) 3.2 6 0.8 4.9 6 0.7 ,0.0005
Triglycerides (mmol/liter) 1.8 6 1.3 3.0 6 1.8 ,0.005
Total/HDL cholesterol 5.0 6 1.3 7.9 6 2.5 ,0.0005
Glucose (mmol/liter) 4.8 6 1.6 4.6 6 0.6 NS
Insulin (pmol/liter) 11.1 6 13.6 11.4 6 9.1 NS
Data are presented as the mean value 6 SD.
HDL and LDL 5 high and low density lipoprotein, respectively; NS 5 not significant.
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0.05; Fig. 2) but not in hypercholesterolemic subjects (Fig.
3). In contrast, there was a significant inverse correlation
between CFR and LDL cholesterol in hypercholesterolemic
(r 5 20.61, p , 0.01; Fig. 3) but not in normocholester-
olemic subjects (Table 4 and Fig. 2). Coronary resistance
was comparable in both groups at rest and during adenosine
(Table 3).
DISCUSSION
In contrast to previous studies in small patient groups, we
found no difference in either rest or hyperemic MBF or
CFR based on TC. There was a weak correlation between
CFR and HDL cholesterol for all subjects, but not between
CFR and LDL cholesterol. However, in hypercholester-
olemic subjects, CFR was inversely related to the LDL
subfraction (20.61, p , 0.01), supporting a pathogenic role
for this lipid subfraction in dysfunction of the coronary
microcirculation. This is in line with an increasing body of
evidence indicating that LDL cholesterol, particularly its
oxidized form, specifically impairs endothelium-dependent
vasodilation by reducing nitric oxide synthesis or initiating
superoxide anion production, or both (15,16,28–30).
Our findings are in agreement with previous results from
Dayanikli et al. (10) and Yokoyama et al. (11,31), who
demonstrated a significant inverse correlation between CFR
and lipid variables, including LDL cholesterol. In contrast
to our results and the results of Guethlin et al. (14),
however, they also found a negative correlation between TC
and CFR. The discrepancies could be explained by different
patient selection, smaller study groups with a narrow,
nonrepresentative range of cholesterol and concomitant
medical therapy in the previous studies. For example,
Dayanikli et al. (10) studied 16 hypercholesterolemic men,
all of whom had a family history; three were smokers and 12
were being treated with lipid-lowering agents. Yokoyama et
al. (31) found a significantly reduced CFR in patients with
familial hypercholesterolemia. However, this must not nec-
essarily be attributed to coronary dysfunction, because the
systemic hemodynamic response to dipyridamole was largely
blunted in patients with familial hypercholesterolemia as
compared with control subjects. Indeed, although dipyrid-
amole increased the rate–pressure product by .30% in
control subjects, it induced an increase of only 10% in
hypercholesterolemic patients. This is in contrast to a report
from Kavey et al. (32), who found an exaggerated blood
pressure response to exercise in patients with increased LDL
cholesterol. It seems that secondary and familial hypercho-
lesterolemia do not necessarily have the same impact on
endothelial function, as the latter could represent an epi-
phenomenon whereby the primary disease would directly
affect the vascular bed. In fact, Pitka¨nen et al. (33) recently
found a correlation between TC and CFR in patients with
familial combined hyperlipidemia and the phenotype IIB,
but not in those with the phenotype IIA, despite increased
total serum cholesterol in both groups. Recent data from the
same group provided the first evidence of linkage to a
subchromosomal region (1q21-23) in familial combined
hyperlipidemia (34). Thus, they convincingly concluded
Table 2. Hemodynamic Data
Control Subjects (n 5 61) Hypercholesterolemic Subjects (n 5 19)
Rest Adenosine Rest Adenosine
HR 62 6 11 90 6 14 61 6 9 93 6 16
SBP 118 6 15 122 6 15 122 6 12 129 6 16
DBP 71 6 11 68 6 10 74 6 8 72 6 8
MAP 87 6 12 87 6 11 90 6 9 92 6 11
RPP 7,290 6 1,779 11,032 6 2,330 7,425 6 1,517 12,097 6 2,828
Data are presented as the mean value 6 SD.
Two-way analysis of variance revealed no significant difference between the two groups, neither at rest nor during adenosine
stimulation.
HR 5 heart rate (beats/min); DBP 5 diastolic blood pressure (mm Hg); MAP 5 mean arterial pressure (mm Hg); RPP 5
rate–pressure product (beats/min 3 mm Hg); SBP 5 systolic blood pressure (mm Hg).
Table 3. Positron Emission Tomographic Measurements
Control Subjects
(n 5 61)
Hypercholesterolemic
Subjects (n 5 19) p Value
MBF at rest (ml/min per g) 0.87 6 0.14 0.84 6 0.14 NS
MBF during adenosine
(ml/min per g)
3.63 6 1.02 3.30 6 0.86 NS
CFR (relative value) 4.23 6 1.29 3.95 6 0.93 NS
Resistance at rest (mm Hg/ml
per min per g)
102 6 21 109 6 20 NS
Resistance during adenosine
(mm Hg/ml per min per g)
26 6 8 30 6 10 NS
Data are presented as the mean value 6 SD.
CFR 5 coronary flow reserve; MBF 5 myocardial blood flow; NS 5 not significant.
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that genetic factors behind familial combined hyperlipid-
emia may cause endothelial or smooth muscle dysfunction,
or both, by mechanisms unrelated to lipid metabolism (33).
Yokoyama et al. (11) also reported decreased CFR in
patients with secondary hypercholesterolemia. However,
after exclusion of the hypertensive subjects from their
analysis, they found no significant difference in CFR be-
tween hypercholesterolemic patients and control subjects
(11). Hypertension was an exclusion criterion in our study,
because it is a well-known confounding factor for endothe-
lial dysfunction (35).
Determinants of CFR. Coronary flow reserve, defined as
the ratio of near maximal to basal MBF, has been proposed
as an indirect variable to evaluate the function of the
coronary circulation (36). It is an integrated measure of
coronary flow through both the large epicardial coronary
arteries and the microcirculation. Therefore, abnormal CFR
can be caused by either narrowing of the epicardial arteries
(22) or dysfunction of the microcirculation (37), even in the
absence of detectable epicardial stenoses. Although, for
ethical reasons, coronary angiography could not be per-
formed on asymptomatic volunteers, the probability of
Figure 1. All subjects.
Figure 2. CFR Versus Lipid Fractions in Controls
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relevant coronary stenosis was very low in our study group,
according to the clinical assessment (19). Dysfunction of the
microcirculation can be caused by 1) structural changes (38)
(i.e., vascular remodeling with a reduced lumen/wall ratio;
2) functional alterations, which may involve neurohumoral
factors (39–41) and/or endothelial dysfunction (1); 3)
alteration of autonomic innervation (42– 45); and 4)
changes in extravascular resistance (e.g., increased intramyo-
cardial pressure).
Endothelium-dependent and -independent coronary hy-
peremic response to adenosine. Until recently, the vaso-
dilator effect of adenosine was thought to be based solely on
direct stimulation of A2-adenosine receptors on vascular
smooth muscle cells, which mediate an increase in the
second messenger cyclic adenosine monophosphate by stim-
ulating adenylate cyclase. Therefore, this agent has been
used frequently in animal as well as human studies to
evaluate endothelium-independent vasodilation (46). How-
ever, in the last decade, it has been appreciated that
adenosine also acts as an endothelial-dependent vasodilator
(47), both through flow-mediated dilation (48) and by
directly stimulating A1-adenosine (49) and other purinergic
(50) receptors on endothelial cells. Therefore, impaired
CFR, as assessed with PET in response to adenosine or
dipyridamole, has been suggested as a surrogate measure of
subclinical coronary disease, providing an integrated mea-
sure of vascular endothelial function and smooth muscle
relaxation (10,33). In fact, CFR assessed during adenosine-
induced hyperemia has been found to relate to
endothelium-dependent vasodilation (51–53). Thus, our
results reflect, at least in part, endothelial function.
Mechanisms of LDL-induced coronary dysfunction.
Endothelial dysfunction has been found to be caused by
several coronary risk factors, such as hypercholesterolemia
(54), essential hypertension (35), diabetes mellitus (55) and
smoking (56). We found a significant inverse correlation
between CFR and LDL cholesterol in hypercholesterolemic
patients. Several mechanisms of LDL-associated vascular
dysfunction have been reported. Reduced endothelial nitric
oxide bioactivity has been demonstrated in hypercholester-
olemic animals and attributed to increased LDL cholesterol
(15,57). The oxidized form of LDL is markedly more
effective than native LDL cholesterol in causing endothelial
(29) and microcirculatory dysfunction (16) by reducing
nitric oxide synthesis (16). In addition, LDL cholesterol has
been shown to increase vascular production of superoxide
anion (16,58,59), which can inactivate nitric oxide rapidly
(60). Dietary correction of hypercholesterolemia (61), long-
term antioxidant therapy (62,63) and polyethylene glycol
superoxide dismutase (64) improve endothelium-dependent
vasodilation by normalizing endothelium superoxide anion
production. Oxidized LDL cholesterol, per se, has been
shown to cause endothelial dysfunction in vitro (65) and to
decrease endothelium-dependent vasodilation in ex vivo
experiments (29,66). Oxidized LDL may also impair the
signal transduction pathways that link endothelial cell sur-
face receptors with nitric oxide production (67,68) and
inhibit nitric oxide synthase activity (69). Recently, en-
hanced endothelin immunoreactivity (70) in the coronary
and systemic circulation and elevated plasma levels (71) of
endothelin have been reported in humans with endothelial
dysfunction, suggesting the possibility that increased endo-
thelin may also contribute to endothelial dysfunction.
Clinical implications. Although we found no difference in
MBF and CFR based on TC, the LDL cholesterol subfrac-
tion correlated inversely with CFR in hypercholesterolemic
subjects who where otherwise normal and totally asymp-
tomatic. This supports a pathogenetic role for the LDL
Figure 3. CFR Versus Lipid Fractions in Hypercholesterolemic Subjects
Table 4. Correlation Between Coronary Vascular Resistance
and Lipids
CVR vs.
Control Subjects
(n 5 61)
Hypercholesterolemic
Subjects
(n 5 19)
r p r p
Total cholesterol 0.11 NS 20.23 NS
HDL cholesterol 0.29 ,0.05 0.14 NS
LDL cholesterol 0.01 NS 20.61 ,0.01
Triglycerides 20.01 NS 0.35 NS
Total/HDL
cholesterol
20.24 NS 20.19 NS
Glucose 20.13 NS 20.26 NS
Insulin 20.33 NS 20.33 NS
CVR 5 coronary vascular resistance; other abbreviations as in Table 1.
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subfraction in coronary dysfunction. Our in vivo results are
in agreement with the previous observations identifying the
LDL subfraction as a cause of endothelial dysfunction, and
extend these findings to the coronary microcirculation in
humans. This provides pathophysiologic support for the
clinical strategy (72) that it is more appropriate to treat the
entire lipid profile rather than to target TC reduction alone.
In fact, risk assessment without taking LDL subfraction
into account seems to provide unreliable results (73). In this
context, it is of particular importance to remember that the
benefits of treating any risk factor depend not only on the
absolute risk of future disease but also on the degree to
which the risk factor in question contributes to this risk
(74). The measurement of CFR with PET in hypercholes-
terolemic patients may not only help to identify those
asymptomatic subjects at highest risk, but also provide a
“target” to assess the functional effectiveness of lipid-
lowering treatment.
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